Monocyte/HDL Ratio and Lymphocyte/Monocyte Ratio in Patients with Pseudoexfoliation Syndrome

References

• Lindberg JG. Clinical investigations on depigmentation of the pupillary border and translucency of the iris in cases of senile cataract and in normal eyes in elderly persons. Acta Ophthalmol Suppl. 1989;190:1–96.
   PubMedGoogle Scholar
• Ritch R, Schlotzer-Schrehardt U. Exfoliation syndrome. Surv Ophthalmol. 2001;45:265–315.
   PubMed Web of Science ®Google Scholar
• Davanger M. On the molecular composition and physico-chemical properties of the pseudo-exfoliation material. Acta Ophthalmol. 1977;55:621–633. doi:10.1111/j.1755-3768.1977.tb05660.x.
   Web of Science ®Google Scholar
• Morrison JC, Green WR. Light microscopy of the exfoliation syndrome. Acta Ophthalmol. 1988;184:5–27.
   Google Scholar
• Schlotzer-Schrehardt UM, Koca MR, Naumann GO, Volkholz H. Pseudoexfoliation syndrome. Ocular manifestation of a systemic disorder? Arch Ophthalmol. 1992;110:1752–1756. doi:10.1001/archopht.1992.01080240092038.
   PubMed Web of Science ®Google Scholar
• Schumacher S, Schlotzer-Schrehardt U, Martus P, Lang W, Naumann GO. Pseudoexfoliation syndrome and aneurysms of the abdominal aorta. Lancet. 2001;357:359–360. doi:10.1016/S0140-6736(00)03645-X.
   PubMed Web of Science ®Google Scholar
• Faschinger C, Schmut O, Wachswender C, Mossböck G. Glaucoma and oxidative stress. Determination of malondialdehyde–a product of lipid peroxidation. Ophthalmologe. 2006;103:953–959. doi:10.1007/s00347-006-1399-3.
   PubMed Web of Science ®Google Scholar
• Sorkhabi R, Ghorbanihaghjo A, Ahoor MH. Oxidative stres in psudoexfoliation syndrome. Indian J Ophthalmol. 2011;23:27–32.
   Google Scholar
• Sorkhabi R, Ghorbanihaghjo A, Javadzadeh A, Rashtchizadeh N, Moharrery M. Oxidative DNA damage and total antioxidant status in glaucoma patients. Mol Vis. 2011;17:41–46.
   PubMed Web of Science ®Google Scholar
• Atalar PT, Atalar E, Kilic H, et al. Impaired systemic endothelial function in patients with pseudoexfoliation syndrome. Int Heart J. 2006;47:77–84.
   PubMed Web of Science ®Google Scholar
• Cumurcu T, Ozyurt H, Demir HD, Yardim H. Serum alpha-1-antitriypsin levels in patients with pseudoexfolative syndrome. Curr Eye Res. 2008;33:159–162. doi:10.1080/02713680701861752.
   PubMed Web of Science ®Google Scholar
• Sorkhabi R, Ghorbanihaghjo A, Ahoor M, Nahaei M, Rashtchizadeh N. High-sensitivity C-reactive protein and tumor necrosis factor alpha in pseudoexfoliation syndrome. Oman Med J. 2013;28:16–19. doi:10.5001/omj.2013.04.
   PubMedGoogle Scholar
• Turkyilmaz K, Oner V, Kırbas A. Serum YKL-40 levels as a novel marker of inflammation and endothelial dysfunction in patients with pseudoexfoliation syndrome. Eye. 2013;27:854–859. doi:10.1038/eye.2013.92.
   PubMed Web of Science ®Google Scholar
• Kurtul BE, Ozer PA, Kabatas EU. Elevated neutrophilto-lymphocyte ratio in pseudoexfoliation syndrome. Eye. 2016;30:1045–1048. doi:10.1038/eye.2016.89.
   PubMed Web of Science ®Google Scholar
• Altintas O, Yuksel N, Sonmez GT. Serum antiphospholipid antibody levels in pseudoexfoliation. J Glaucoma. 2012;21:326–330. doi:10.1097/IJG.0b013e31821206cd.
   PubMed Web of Science ®Google Scholar
• Ucar FM. A potential marker of bare metal stent restenosis: monocyte count-to-HDL cholesterol ratio. BMC Cardiovasc Disord. 2016;16:186. doi:10.1186/s12872-016-0371-7.
   PubMed Web of Science ®Google Scholar
• Kormaz A, Demir M, Unal S, et al. Monocyte-to-high density lipoprotein ratio (MHR) can predict the significance of angiographically intermediate coronary lesions. Int J Cardiovasc Acad. 2017;3:16–20. doi:10.1016/j.ijcac.2017.05.008.
   Google Scholar
• Canpolat U, Çetin EH, Cetin S, et al. Association of monocyte-to-HDL cholesterol ratio with slow coronary flow is linked to systemic inflammation. Clin Appl Thromb Hemost. 2016;22:476–482. doi:10.1177/1076029615594002.
   PubMed Web of Science ®Google Scholar
• Kanbay M, Solak Y, Unal HU, et al. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol. 2014;46:1619–1625. doi:10.1007/s11255-014-0730-1.
   PubMed Web of Science ®Google Scholar
• Cetin MS, Ozcan Cetin EH, Kalender E, et al. Monocyte to HDL cholesterol ratio predicts coronary artery disease severity and future major cardiovascular adverse events in acute coronary syndrome. Heart Lung Circ. 2016;25:1077–1086. doi:10.1016/j.hlc.2016.02.023.
   PubMed Web of Science ®Google Scholar
• Song W, Wang K, Zhang R, Zou S. Prognostic value of the lymphocyte monocyte ratio in patients with colorectal cancer: a meta-analysis. Amornyotin. S, ed. Medicine. 2016;95(49):e5540. doi:10.1097/MD.0000000000004864.
   PubMed Web of Science ®Google Scholar
• Yue S, Zhang J, Wu J, et al. Use of the monocyte-to-lymphocyte ratio to predict diabetic retinopathy. Int J Environ Res Public Health. 2015;12:10009–10019. doi:10.3390/ijerph120810009.
   PubMed Web of Science ®Google Scholar
• Li W, Ma G, Wu Q, Deng Y, Wang Y. Prognostic value of lymphocyte-to-monocyte ratio among Asian lung cancer patients. Oncotarget. 2017;66:110606–110613.
   Google Scholar
• Li W, Tao L, Zhang L, Xiu D. Prognostic role of lymphocyte to monocyte ratio for patients with pancreatic cancer. Onco Targets Ther. 2017;10:3391–3397. doi:10.2147/OTT.S142022.
   PubMed Web of Science ®Google Scholar
• Scharfenberg E, Schlötzer-Schrehardt U. PEX syndrome: clinicaldiagnosis and systemic manifestations. Ophthalmologe. 2012;109:952–961. doi:10.1007/s00347-012-2534-y.
   PubMed Web of Science ®Google Scholar
• Thorleifsson G, Magnusson KP, Sulem P, et al. Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. Science. 2007;317:1397–1400. doi:10.1126/science.1146554.
   PubMed Web of Science ®Google Scholar
• Kesler A, Irge D, Rogowski O, et al. High-sensitivity Creactive protein measurements in patients with non-arteritic anterior ischemic optic neuropathy: a clue to the presence of a microinflammatory response. Acta Ophthalmol. 2009;87:216–221. doi:10.1111/j.1755-3768.2008.01199.x.
   PubMed Web of Science ®Google Scholar
• Leibovitch I, Kurtz S, Kesler A, Feithliher N, Shemesh G, Sela BA. C-reactive protein levels in normal tension glaucoma. J. Glaucoma. 2005;14:384–386.
   PubMed Web of Science ®Google Scholar
• Su WW, Cheng ST, Ho WJ, Tsay PK, Wu SC, Chang SH. Glaucoma is associated with peripheral vascular endothelial dysfunction. Ophthalmology. 2008;115:1173–1178. doi:10.1016/j.ophtha.2007.10.026.
   PubMed Web of Science ®Google Scholar
• Yüksel N, Pirhan D, Altintaş O, Cağlar Y. Systemic high-sensitivity C-reactive protein level in pseudoexfoliation syndrome and pseudoexfoliation glaucoma. J Glaucoma. 2010;19:373–376. doi:10.1097/IJG.0b013e3181bdb570.
   PubMed Web of Science ®Google Scholar
• Visontai Z, Merisch B, Kollai M, Hollo G. Increase of carotid artery stiffness and decrease of baroreflex sensitivity in exfoliation syndrome and glaucoma. Br J Ophthalmol. 2006;90:563–567. doi:10.1136/bjo.2005.087908.
   PubMed Web of Science ®Google Scholar
• French DD, Margo CE, Harman LE. Ocular pseudoexfoliation and cardiovascular disease: a national cross-section comparison study. N Am J Med Sci. 2012;4:468–473. doi:10.4103/1947-2714.101987.
   PubMedGoogle Scholar
• Wang W, He M, Zhou M, et al. Ocular pseudoexfoliation syndrome and vascular disease: A systematic review and meta-analysis. PLoS One. 2014;9(3):e92767. doi:10.1371/journal.pone.0092767.
   PubMed Web of Science ®Google Scholar
• Tipping RW, Ford CE, Pressel SL, et al. The emerging risk factors collaboration: major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993–2000. doi:10.1001/jama.2009.1619.
   PubMed Web of Science ®Google Scholar
• Kurtul BE, Kurtul A, Altiaylik OP, Kabatas EU, Ertugrul GT. Serum lipid levels in pseudoexfoliation syndrome. Semin Ophthalmol. 2017;32:281–284. doi:10.3109/08820538.2015.1068341.
   PubMed Web of Science ®Google Scholar
• Lesiewska H, Malukiewicz G, Mańkowska‐Cyl A, Odrowąż‐Sypniewska G. Lipids and C‐reactive protein as vascular risk markers in pseudoexfoliation syndrome. Acta Ophthalmol. 2016;94:380–381. doi:10.1111/aos.12664.
   PubMed Web of Science ®Google Scholar
• Ancuta P, Jianbin W, Gabuzda D. CD16+ monocytes produce IL-6, CCL2 and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells. J Leukoc Biol. 2006;80:1156–1164. doi:10.1189/jlb.0206125.
   PubMed Web of Science ®Google Scholar
• Hessler JR, Robertson AL Jr, Chisolm GM III. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis. 1979;32:213–229. doi:10.1016/0021-9150(79)90166-7.
   PubMed Web of Science ®Google Scholar
• Murphy AJ, Woollard KJ. High-density lipoprotein: a potent inhibitor of inflammation. Clin Exp Pharmacol Physiol. 2010;37:710–718. doi:10.1111/j.1440-1681.2009.05338.x.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Baker PW, Rye KA. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol. 2002;13:285–288. doi:10.1097/00041433-200206000-00008.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004;95:764–772. doi:10.1161/01.RES.0000146094.59640.13.
   PubMed Web of Science ®Google Scholar